Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
Entrada Therapeutics, Inc. executive Sethuraman Natarajan, President of Research & Development, reported an open-market sale of 25,907 shares of Common Stock at a weighted average price of $15.3939 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024, and Natarajan now directly holds 216,317 shares.
Entrada Therapeutics President & COO Nathan J. Dowden reported an option exercise and related share sale. He exercised stock options to acquire 15,000 shares of common stock at $1.74 per share, then sold 15,000 shares of common stock in an open-market transaction at a weighted average price of $15.3302 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. Following the sale, Dowden directly owns 198,588 shares of common stock and holds 49,831 stock options exercisable for common stock as of the reported date.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the sale of 15,000 shares of Common Stock on 05/04/2026 following the exercise of stock options for cash. The filing also lists multiple 10b5-1 sales by Nathan Dowden in March 2026 with per-trade share counts and proceeds.
TRDA notice of proposed sale of 25,907 restricted stock units. The filing lists the securities type as Restricted Stock Units with an award date of 03/01/2025. The filing also discloses prior sales in the past three months of 7,577 and 3,898 common shares, with proceeds shown as $89,078.24 and $45,442.49.
Entrada Therapeutics will hold its 2026 annual shareholder meeting virtually on June 10, 2026, for holders of its 38,820,616 outstanding common shares as of April 13, 2026. Stockholders will vote on electing two Class II directors, ratifying Ernst & Young as auditor for 2026, and approving amendments to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan.
The equity plan amendments would revise each plan’s 4%/1% annual “evergreen” formula so that outstanding pre-funded warrants, currently 3,367,003, are treated as outstanding shares when calculating future automatic share pool increases. The board argues this keeps equity capacity aligned with total capitalization and supports hiring and retention without shifting heavily toward cash compensation.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 2,500 shares of Common Stock in an open-market transaction. The sale occurred at a price of $12.95 per share. After the trade, he directly holds 119,010 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 6, 2025, indicating it was pre-scheduled.
TRDA issuer filed a Form 144 to sell 2,500 shares of Common Stock. The notice lists the securities as previously exercised stock options with a cash sale method dated 03/15/2024. The filing also reports recent Rule 10b5-1 sales by Kory Wentworth on 03/10/2026 (11,388 shares), 03/09/2026 (5,089 shares), 03/04/2026 (7,988 shares), 03/03/2026 (5,712 shares) and 03/02/2026 (2,939 shares).
Entrada Therapeutics President & COO Nathan J. Dowden reported open-market sales of a total of 15,010 shares of common stock. He sold 3,116 shares on March 9, 2026 at a weighted average price of $13.024 per share and 11,894 shares on March 10, 2026 at a weighted average price of $13.0476 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the most recent sale, Dowden directly holds 198,588 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. Chief Financial Officer Kory James Wentworth reported open-market sales of company common stock. He sold 5,089 shares on March 9, 2026 at a weighted average price of $13.0011 per share and 11,388 shares on March 10, 2026 at a weighted average price of $13.0151 per share. These transactions, totaling 16,477 shares, were executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2025. After the most recent sale, he directly holds 121,510 shares of Entrada common stock.